Literature DB >> 8554451

Immunophenotype of intraductal carcinoma.

S Bose1, M L Lesser, L Norton, P P Rosen.   

Abstract

OBJECTIVE: Mammography and breast-conserving therapy have focused attention on the classification of intraductal carcinoma (IDC) and emphasized the prognostic importance of comedo versus noncomedo variants. We used histochemical markers to define the immunophenotype of 43 IDCs with respect to comedo versus noncomedo status and patterns of angiogenesis.
RESULTS: Reactions in comedo carcinomas were significantly negative for estrogen receptor and progesterone receptor, and positive for p53 and HER-2/neu more often than the noncomedo variant. All seven IDCs associated with Paget's disease showed positive reactions for HER-2/neu. Basement membrane immunoreactivity for type IV collagen and laminin was discontinuous in most examples of IDC regardless of type, with a trend toward more intense staining in comedo than in noncomedo carcinomas. Periductal angiogenesis was not significantly related to the type of IDC but was more pronounced with comedo carcinomas.
CONCLUSIONS: These observations indicate that there are immunophenotypic correlates to the current structural classification of IDC. The immunophenotype of IDC is helpful in subclassifying an IDC and could prove useful as a prognostic indicator for local control in patients treated by breast-conserving therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8554451

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

Review 1.  [Anatomy of the breast].

Authors:  W Böcker; D Hungermann; T Decker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

2.  Evaluation of three-dimensional arterial spin labeling perfusion imaging for the pathological investigation of musculoskeletal tumors.

Authors:  Lingbin Xu; Leiming Xu; Haidong Zhu
Journal:  Exp Ther Med       Date:  2018-04-03       Impact factor: 2.447

Review 3.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

4.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

5.  Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer.

Authors:  Andrei Dobrescu; Monique Chang; Vatsala Kirtani; George K Turi; Randa Hennawy; Alexander A Hindenburg
Journal:  ISRN Oncol       Date:  2011-07-19

Review 6.  Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.

Authors:  Flora Zagouri; Theodoros N Sergentanis; George C Zografos
Journal:  World J Surg Oncol       Date:  2007-05-31       Impact factor: 2.754

7.  Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography.

Authors:  Vassilios Papantoniou; Spyridon Tsiouris; Ekaterini Mainta; Varvara Valotassiou; Michael Souvatzoglou; Maria Sotiropoulou; Lydia Nakopoulou; Dimitrios Lazaris; Androniki Louvrou; Maria Melissinou; Artemis Tzannetaki; Ioannis Pirmettis; John Koutsikos; Cherry Zerva
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

Review 8.  Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Authors:  Kylie L Gorringe; Stephen B Fox
Journal:  Front Oncol       Date:  2017-10-23       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.